CANDIDA ALBICANS SURFACE ANTIGENS

长期目标是确定表面抗原的特征 白色念珠菌在体内外的表达 发展，确定单抗是否针对 这些抗原可用于白念珠菌的生物型菌株，以及 提取和化学表征抗原，这些抗原可能是 在发病机制中很重要。第一个目标将通过以下方式实现 表面特异性单抗文库的建立 白色念珠菌的抗原，并将其与 免疫胶体金电子显微镜技术。这个 第二个目标将需要与许多 在特定条件下生长的真菌菌株。第三 目标将通过使用突变体来鉴定病原菌 用于提纯抗原的决定簇和单抗 从细胞壁萃取物中提取。 为了诱导对许多表面抗原的抗体反应，小鼠将 被免疫到各种细胞壁和其他亚细胞 分数。一些细胞壁组分将被浓缩为菌丝- 特定的抗原。产生的单抗的特异性 致敏脾细胞与浆细胞瘤细胞的融合 将通过交叉免疫电泳法进行测定。 各种抗体将被用来检测抗原表达 在许多白色念珠菌和其他酵母菌中确定 如果这些抗体可以用于白念珠菌菌株的生物分型。 此外，选择的抗原表达的特征 菌株将通过跟踪酵母菌和菌丝在 在体外和体内水平上进行电子显微镜分析。 这些研究将提供有关以下方面的全面知识 念珠菌抗原表达的稳定性或变异性 在这种疾病的小鼠模型中发生的球虫病。一个 库中各种抗原的单抗将被 作为这项工作的结果，这些抗体将被 用于选择不能产生特定表面的突变体 行列式。这些突变体的毒力将在小鼠身上进行测试 确定哪些抗原可能相关的念珠菌病模型 导致疾病的能力。这样的抗原将被分离出来 从野生型菌株中分离出来，并进行了化学特征分析。

The long term objectives are to characterize the surface antigens expressed by Candida albicans during in vitro and in vivo development, determine if monoclonal antibodies raised against these antigens may be used to biotype strains of C. albicans, and extract and chemically characterize antigens which may be important in pathogenesis. The first objective will be done by establishing a bank of monoclonal antibodies specific for surface antigens of C. albicans and use these in conjunction with immunocolloidal gold electron microscopic techniques. The second objective will entail reacting the antibodies with many strains of the fungus grown under specified conditions. The third objective will be done by using mutants to identify pathogenetic determinants and monoclonal antibodies to purify the antigens from cell wall extracts. To induce antibody responses to many surface antigens, mice will be immunized to a variety of cell wall and other subcellular fractions. Some cell wall fractions will be enriched for hyphal- specific antigens. Specificities of monoclonal antibodies resulting from fusions of sensitized spleen cells with plasmacytoma cells will be determined by crossed immunoelectrophoretic techniques. The various antibodies will be used to detect antigen expression among many isolates of C. albicans and other yeasts to determine if the antibodies could be used for biotyping C. albicans strains. In addition, characterization of antigen expression on selected strains will be done by following yeast and hyphal development in vitro and in vivo at the level of electron microscopic analysis. These studies will provide comprehensive knowledge concerning the stability or variability of candidal antigen expression during development of cadidiasis in a murine model of this disease. A bank of monoclonal antibodies to the various antigens will be developed as a result of this work and these antibodies will be used to select mutants unable to produce a particular surface determinant. Virulence of these mutants will be tested in mouse models of candidiasis to ascertain which antigens may be related to the ability to cause disease. Such antigens will be isolated from wild type strains and chemically characterized.